Trade ADMA Biologics, Inc. - ADMA CFD

Trading Conditions

• TypeThis financial instrument is available for trading through CFDs and Knock-outs.Knock-out options available only for selected countries.Learn more about:CFDsKnock-outs:
  CFD

  

  Knock-out

  
• Spread: 0.028
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.022124 %(-$1.11)Trade size with leverage ~ $5,000.00Money from leverage ~$4,000.00Go to platform: -0.02212%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000099 %(-$0.00)Trade size with leverage ~ $5,000.00Money from leverage ~$4,000.00Go to platform: -0.00010%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.022124 %
  (-$1.11)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000099 %
  (-$0.00)

Key Stats

• Prev. Close: 9.491
• Open: 9.471
• 1-Year Change: -40.27%
• Day's Range: 9.471 - 9.811

Trade ADMA Biologics, Inc. - ADMA

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.